Sponsored Links
| Soligenix Announces Initiation Of Its Confirmatory Phase 3 Clinical Trial Of OrBec(R) In Acute GI GVHD |
 |
 |
 |
| Pharmacy - Pharma Industry - Biotech Industry | |||
|
Soligenix, Inc., (Soligenix or the Company) (OTC Bulletin Board: SNGX), formerly known as DOR BioPharma, Inc., a late-stage biotechnology company, announced that it has initiated enrollment in its confirmatory Phase 3 randomized, double-blind, placebo-controlled, multicenter clinical trial evaluating orBec(®) for the treatment of acute gastrointestinal Graft-versus-Host disease (GI GVHD). Read more: Pharma Industry / Biotech Industry News From Medical News Today
|